Quantitative texture analysis of EUS images accurately differentiates pancreatic cancer from normal tissue and may obviate the need for EUS-FNA

Endoscopy ◽  
2006 ◽  
Vol 39 (S 1) ◽  
Author(s):  
A Das ◽  
F Li ◽  
C Nguyen
Keyword(s):  
Pancreatic Cancer ◽  
Texture Analysis ◽  
Normal Tissue

scholarly journals Computer-aided diagnosis in mammography: classification of mass and normal tissue by texture analysis

1994 ◽  
Vol 39 (12) ◽  
pp. 2273-2288 ◽  
Author(s):  
A Petrosian ◽  
Heang-Ping Chan ◽  
M A Helvie ◽  
M M Goodsitt ◽  
D D Adler
Keyword(s):  
Texture Analysis ◽  
Normal Tissue ◽  
Computer Aided Diagnosis ◽  
Computer Aided ◽  
Aided Diagnosis

scholarly journals Dosimetric and radiobiological comparison of treatment plan between CyberKnife and EDGE in stereotactic body radiotherapy for pancreatic cancer

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Zhi-tao Dai ◽  
Li Ma ◽  
Ting-ting Cao ◽  
Lian Zhu ◽  
Man Zhao ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Spinal Cord ◽  
Stereotactic Body Radiotherapy ◽  
Dose Distribution ◽  
Normal Tissue ◽  
Organs At Risk ◽  
Treatment Plan ◽  
Locally Advanced ◽  
Conformity Index ◽  
Homogeneous Dose

AbstractTo perform a comparison of the different stereotactic body radiotherapy (SBRT) plans between the Varian EDGE and CyberKnife (CK) systems for locally advanced unresectable pancreatic cancer. Fifteen patients with pancreatic cancer were selected in this study. The median planning target volume (PTV) was 28.688 cm3 (5.736–49.246 cm3). The SBRT plans for the EDGE and CK were generated in the Eclipse and Multiplan systems respectively with the same contouring and dose constrains for PTV and organs at risk (OARs). Dose distributions in PTV were evaluated in terms of coverage, conformity index (CI), new conformity index (nCI), homogeneity index (HI), and gradient index (GI). OARs, including spinal cord, bowel, stomach, duodenum and kidneys were statistically evaluated by different dose-volume metrics and equivalent uniform dose (EUD). The volume covered by the different isodose lines (ISDL) ranging from 10 to 100% for normal tissue were also analyzed. All SBRT plans for EDGE and CK met the dose constraints for PTV and OARs. For the PTV, the dosimetric metrics in EDGE plans were lower than that in CK, except that D99 and GI were slightly higher. The EDGE plans with lower CI, nCI and HI were superior to generate more conformal and homogeneous dose distribution for PTV. For the normal tissue, the CK plans were better at OARs sparing. The radiobiological indices EUD of spinal cord, duodenum, stomach, and kidneys were lower for CK plans, except that liver were higher. The volumes of normal tissue covered by medium ISDLs (with range of 20–70%) were lower for CK plans while that covered by high and low ISDLs were lower for EDGE plans. This study indicated that both EDGE and CK generated equivalent plan quality, and both systems can be considered as beneficial techniques for SBRT of pancreatic cancer. EDGE plans offered more conformal and homogeneous dose distribution for PTV, while the CK plans could minimize the exposure of OARs.

CRM1 expression in pancreatic carcinoma.

2013 ◽  
Vol 31 (15_suppl) ◽  
pp. e15115-e15115 ◽  
Author(s):  
Amit Mahipal ◽  
Domenico Coppola ◽  
Shilpa Gupta ◽  
Barbara Centeno ◽  
Mokenge Peter Malafa
Keyword(s):  
Pancreatic Cancer ◽  
Pancreatic Carcinoma ◽  
Anticancer Agents ◽  
Normal Tissue ◽  
Tissue Sample ◽  
Pancreatic Tissue ◽  
Ductal Adenocarcinoma ◽  
Cancer Tissue ◽  
Tissue Samples ◽  
Paired Samples

e15115 Background: Increased expression of chromosomal region maintenance (CRM1) protein, also known as exportin 1, has been described in several human cancers. It is an important regulator of subcellular localization of tumor suppressor proteins and growth regulatory proteins. Direct inhibition of CRM1 blocks cell proliferation and induces apoptosis leading to the current evaluation of CRM1 inhibitors as anticancer agents in early phase clinical trials. There is a paucity of data regarding the prevalence of CRM1 expression in pancreatic cancer. Methods: We analyzed the expression of CRM1 by immunohistochemistry (IHC) in pancreatic tissue microarray (TMA) samples (malignant and non-malignant) obtained from patients who underwent potentially curative resection for pancreatic ductal adenocarcinoma. CRM1 antibody (Santa Cruz Biotechnology) was used for immunostaining the formalin fixed paraffin embedded core sections in the TMA samples. The intensity of staining and percentage of cells stained were graded on a scale of 0 to 3, with 3 being highest. The final IHC score was obtained using the product of immunostain intensity and percentage of cells stained (Range: 0-9). Low and high CRM1 expression was considered if the IHC score was 0 to 4 and 6 to 9 respectively. Results: Seventy nonmalignant and 91 pancreatic carcinoma samples were evaluated in this study. The median IHC score was 6 (range: 0-9) and 3 (range: 1-9) in malignant and nonmalignant pancreatic tissue samples respectively (P<0.0001). High CRM1 expression was found in 11% (8/70) of normal tissue samples and 69% (63/91) of tumor samples (P<0.0001). There were 48 paired samples of pancreatic cancer tissue and normal tissue obtained from same patient. Among these patients, 33 (69%) patients had higher CRM1 expression, 7 (15%) patients had similar expression and 8 (17%) patients had lower expression in malignant tissue sample as compared to their adjacent normal tissues. Conclusions: Higher CRM1 expression occurs frequently in pancreatic cancer as compared to nonmalignant pancreatic tissue, reinforcing its putative tumor oncogenic activity, and raising the value of targeting it for pancreatic cancer therapy.

scholarly journals Pharmacokinetic Analysis of Dynamic [18F]FAZA PET Imaging in Pancreatic Cancer Patient

2020 ◽  
Author(s):  
Fiona Li ◽  
Edward Taylor ◽  
Ivan Yeung ◽  
David Jaffray ◽  
Ur Metser ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Kinetic Parameters ◽  
Normal Tissue ◽  
Pancreatic Tissue ◽  
Distribution Volume ◽  
Information Criteria ◽  
Pharmacokinetic Analysis ◽  
Time Activity ◽  
Normal Pancreatic Tissue ◽  
Pet Tracer

Abstract Purpose This study assessed the pharmacokinetics of the hypoxia PET tracer, [18F]fluoroazomycin arabinoside ([18F]FAZA), in pancreatic cancer (PCa) patients and determined the optimal kinetic parameters to distinguish cancerous from normal pancreatic tissue. Method Twenty patients with pancreatic ductal adenocarcinoma underwent dynamic [ 18 F]FAZA scans. The tissue time activity curve (TAC) was analyzed using graphical methods to determine reversibility of tracer binding and with standard compartment (S2TC) model and flow modified two tissue compartment (F2TC) model, developed to incorporate transit time of tracer through the blood vessel, to estimate the kinetic parameters. The optimal parameter set to distinguish hypoxic tumors from normal tissues was determined using logistic regression. Results Both graphical and kinetic model analysis indicated that tracer was reversibly bound. According to the Akaike Information Criteria, the F2TC model fitted the tumor TAC better than the S2TC model. Total distribution volume, V T , estimated by the F2TC model for both tumor and normal pancreatic tissue was not significant but that estimated by the S2TC model was significantly different from Logan graphical analysis. The extravascular distribution volume ( DV ) and tracer dissociation rate constant ( k 4 ) can classify hypoxic PCa from normal tissue with sensitivity of 95% and negative predictive value of 89% (P<0.01). Conclusions Kinetic analysis of dynamic [ 18 F]FAZA PET can distinguish PCa from normal tissue with high sensitivity. The reversibility of [ 18 F]FAZA binding in hypoxic cells could be due to glutathionylation of the nitroreductase reduced products and their subsequent efflux from same cells via the ATP mediated multidrug resistant protein (MRP-1) efflux pump.

scholarly journals BCN057, a Modulator of GSK3b Induces KRAS G12D Mutant Pancreatic Cancer Cell Death

2021 ◽  
Author(s):  
Elizabeth M Singer ◽  
Rishi Mann Chugh ◽  
Payel Bhanja ◽  
Adrian Gomez ◽  
Lucy Gao ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Cancer Cells ◽  
Small Molecule ◽  
Normal Tissue ◽  
Synthetic Lethality ◽  
Human Pancreatic Cancer ◽  
Oncogenic Ras ◽  
Cancer Cell Death ◽  
Pancreatic Cancer Cells ◽  
Normal Tissue Toxicity

Effective treatment for Pancreatic Cancer remains a major challenge due to its resistance to radiation/chemotherapy and poor drug permeability. Moreover, treatment induced normal tissue toxicity, mainly to the duodenum and gastrointestinal epithelium, is common and is a dose limiting event, while toxicity to the pancreas is relatively rare. Gastrointestinal toxicity, however, often results in interruption, reduction or premature withdrawal of anti–cancer therapy which is a very significant factor impacting the overall survival of patients being treated. Therefore, development of a therapeutic strategy to selectively sensitize tumor tissue without inducing normal tissue toxicity is important. In this manuscript, we show that the novel small molecule BCN057 can modulate chemo–sensitivity of oncogenic RAS pancreatic cancer cells while conversely protecting normal intestinal epithelium from off target toxicity. In particular, BCN 057 protects Lgr5 positive intestinal stem cells, thereby preserving barrier function. Further, it is demonstrated that BCN057 inhibits GSK3β and thereby induces a pro apoptotic phosphorylation pattern on c–Jun in KRAS G12D mutant pancreatic cancer cells (Panc1) leading to the restoration of PTEN expression and consequent apoptosis. This appears to be a new mechanistic observation for the oncogenic RAS phenotype. Lastly, concurrent with its GSK3β inhibition, BCN057 is a small molecule inhibitor of PD–1 expression on human T–lymphocytes co cultured with human pancreatic cancer cells. In summary, BCN057 can promote synthetic lethality specifically to malignant cells and therefore should be considered to improve the therapeutic ratio in pancreatic and epithelial cancer treatment in conjunction with chemotherapy and radiation.

Clinical Diagnosis of Pancreatic Cancer Using Texture Analysis in Endoscopic Ultrasonography

2019 ◽  
Vol 9 (9) ◽  
pp. 1844-1848
Author(s):  
Jia Fan ◽  
Bo Min ◽  
Feng Xu ◽  
Peng Yang ◽  
Hongwei Ye ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Texture Analysis ◽  
Clinical Diagnosis ◽  
Endoscopic Ultrasonography

Evaluation of Normal Tissue Exposure in Patients Receiving Radiation Therapy for Pancreatic Cancer Based on RTOG 0848

2014 ◽  
Vol 90 (1) ◽  
pp. S358-S359
Author(s):  
T.C. Ling ◽  
J.M. Slater ◽  
R. Mifflin ◽  
P. Nookala ◽  
R. Grove ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Radiation Therapy ◽  
Normal Tissue
Sign in / Sign up

Export Citation Format

Share Document